Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study.
Gondran C, Dumas PY, Bérard E, Bidet A, Delabesse E, Tavitian S, Leguay T, Huguet F, Borel C, Forcade E, Vergez F, Vial JP, Rieu JB, Lechevalier N, Luquet I, Canali A, Klein E, Sarry A, de Grande AC, Pigneux A, Récher C, Largeaud L, Bertoli S. Gondran C, et al. Among authors: lechevalier n. Blood Cancer J. 2024 May 31;14(1):91. doi: 10.1038/s41408-024-01069-9. Blood Cancer J. 2024. PMID: 38821940 Free PMC article.
Dismal outcome of refractory or relapsing patients with myelodysplasia-related acute myeloid leukemia partially alleviated by intensive chemotherapy.
Leroy H, Gadaud N, Bérard E, Klein E, Luquet I, Vial JP, Rieu JB, Lechevalier N, Tavitian S, Leguay T, Largeaud L, Bidet A, Delabesse E, Sarry A, de Grande AC, Récher C, Pigneux A, Bertoli S, Dumas PY. Leroy H, et al. Among authors: lechevalier n. Cancer Med. 2024 Feb;13(3):e7003. doi: 10.1002/cam4.7003. Cancer Med. 2024. PMID: 38400682 Free PMC article.
Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study.
Didi I, Alliot JM, Dumas PY, Vergez F, Tavitian S, Largeaud L, Bidet A, Rieu JB, Luquet I, Lechevalier N, Delabesse E, Sarry A, De Grande AC, Bérard E, Pigneux A, Récher C, Simoncini D, Bertoli S. Didi I, et al. Among authors: lechevalier n. Leuk Res. 2024 Jan;136:107437. doi: 10.1016/j.leukres.2024.107437. Epub 2024 Jan 9. Leuk Res. 2024. PMID: 38215555 Free article.
Principal component analysis yields results comparable to those of an elaborate Boolean strategy: simplifying the assessment of measurable residual disease in chronic lymphocytic leukemia patients.
Brett VE, Dilhuydy MS, Lechevalier N, Adjibabi AN, Gros FX, Forcade É, Letestu R, Vial JP. Brett VE, et al. Among authors: lechevalier n. Ann Biol Clin (Paris). 2023 Oct 20;81(4):379-387. doi: 10.1684/abc.2023.1826. Ann Biol Clin (Paris). 2023. PMID: 37864443
The presence of a chromosomal abnormality in cytopenia without dysplasia identifies a category of high-risk clonal cytopenia of unknown significance.
Brett VE, Lechevalier N, Trimoreau F, Dussiau C, Dimicoli-Salazar S, Coster L, Luquet I, Nadal N, Ribourtout B, Chapiro E, Lefebvre C, Tondeur S, Balducci E, Nguyen-Khac F, Borie C, Radford-Weiss I, Barin C, Eclache V, Mansier O, Bidet A; Groupe Francophone de Cytogénétique Hématologique (GFCH). Brett VE, et al. Among authors: lechevalier n. Genes Chromosomes Cancer. 2023 Mar;62(3):139-151. doi: 10.1002/gcc.23107. Epub 2022 Nov 30. Genes Chromosomes Cancer. 2023. PMID: 36412977
Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia.
Canali A, Vergnolle I, Bertoli S, Largeaud L, Nicolau ML, Rieu JB, Tavitian S, Huguet F, Picard M, Bories P, Vial JP, Lechevalier N, Béné MC, Luquet I, Mansat-De Mas V, Delabesse E, Récher C, Vergez F. Canali A, et al. Among authors: lechevalier n. Clin Cancer Res. 2023 Jan 4;29(1):134-142. doi: 10.1158/1078-0432.CCR-22-2237. Clin Cancer Res. 2023. PMID: 36318706
Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia.
Vergez F, Largeaud L, Bertoli S, Nicolau ML, Rieu JB, Vergnolle I, Saland E, Sarry A, Tavitian S, Huguet F, Picard M, Vial JP, Lechevalier N, Bidet A, Dumas PY, Pigneux A, Luquet I, Mansat-De Mas V, Delabesse E, Carroll M, Danet-Desnoyers G, Sarry JE, Récher C. Vergez F, et al. Among authors: lechevalier n. Blood Cancer J. 2022 Aug 16;12(8):117. doi: 10.1038/s41408-022-00712-7. Blood Cancer J. 2022. PMID: 35973983 Free PMC article.
Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes.
Galtier J, Alric C, Bérard E, Leguay T, Tavitian S, Bidet A, Delabesse E, Rieu JB, Vial JP, Vergez F, Lechevalier N, Luquet I, Klein E, de Grande AC, Sarry A, Pigneux A, Récher C, Bertoli S, Dumas PY. Galtier J, et al. Among authors: lechevalier n. Blood Cancer J. 2021 Nov 13;11(11):180. doi: 10.1038/s41408-021-00551-y. Blood Cancer J. 2021. PMID: 34775463 Free PMC article. No abstract available.
22 results